查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594677

光学疾病治疗市场：按处方类型、治疗方法和最终用户划分 - 全球预测 2025-2030

Optical Disorders Drugs Market by Prescription Type (Over-The-Counter Drugs, Prescription Ophthalmic Drugs), Therapeutics (Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年，光学疾病治疗市场估值为31.4亿美元，预计到2024年将达到35.6亿美元，复合年增长率为13.29%，预计到2030年将达到75.4亿美元。

光学疾病治疗市场的范围包括旨在治疗各种眼科疾病的药物，例如青光眼、黄斑部病变、糖尿病视网膜病变和白内障。这些药物通常透过降低眼压、减缓疾病进展和预防感染来发挥作用，对于维持眼睛健康和视力至关重要。由于人口老化以及糖尿病和其他影响视力的健康状况的增加，眼部疾病的盛行率不断增加，证明了对此类药物的需求。这些治疗方法适用于医院、诊所和居家医疗机构，并具有广泛的最终用途。

主要市场统计
基准年[2023] 31.4亿美元
预测年份 [2024] 35.6亿美元
预测年份 [2030] 75.4亿美元
复合年增长率（%） 13.29%

市场成长受到配方和给药方法技术进步、医疗保健支出增加（尤其是在新兴经济体）以及预防性眼部保健意识提高的显着影响。基因治疗、个人化医疗以及缓释性植入等新型药物输送系统的开发等领域的技术创新提供了充满希望的机会。值得注意的是，生物技术公司和研究机构之间的研究合作和伙伴关係正在推动市场发展。

然而，市场面临一些挑战，包括研发成本上升导致治疗费用昂贵、监管障碍减缓了医药品认证过程以及欠发达地区的准入有限。此外，竞争格局非常激烈，许多公司都在争夺市场占有率，这可能会导致高昂的定价压力。

为了利用市场机会，公司应该专注于有潜力在治疗功效和患者结果方面带来突破的研究领域，例如再生医学和生技药品。也建议投资数位健康解决方案和远距眼科，以有效进入服务不足的市场。市场的本质是动态的，受到快速的技术进步和不断变化的患者需求的驱动，需要持续创新和策略适应性来保持成长和相关性。

市场动态：快速发展的光学疾病治疗市场的关键市场洞察

供需的动态交互作用正在改变光学疾病治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 由于数位化接触增加和不健康的生活方式导致需求增加
    • 老年人口眼相关疾病的盛行率
    • 隐形眼镜使用增加和相关疾病
  • 市场限制因素
    • 新兴经济体治疗费用高且缺乏医疗保险
  • 市场机会
    • 光学化学技术进步
    • 青光眼盛行率上升和医疗支出增加
  • 市场挑战
    • 药物对健康的不良影响

波特五力：驾驭视科疾病药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解外部对眼科疾病药物市场的影响

外部宏观环境因素在塑造视神经疾病治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解眼科疾病治疗药物市场的竞争状况

对光学疾病治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵光学疾病治疗市场供应商的绩效评估

FPNV定位矩阵是评估光学疾病治疗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议，以规划光学疾病治疗市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对光学疾病治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 由于数位化接触增加和不健康的生活方式导致需求增加
      • 老年人眼相关疾病的盛行率
      • 隐形眼镜使用率和相关疾病的增加
    • 抑制因素
      • 新兴经济体的治疗费用高且缺乏健康保险
    • 机会
      • 视力矫正药物的技术进步
      • 青光眼发生率上升和医疗费用上升
    • 任务
      • 药物对健康的不良影响
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依处方笺的眼科疾病治疗药物市场

  • 非处方药
  • 处方眼药

第七章 光学疾病治疗药物市场治疗

  • 老龄化黄斑部病变
  • 结膜炎
  • 糖尿病黄斑部水肿
  • 糖尿病视网膜病变
  • 干眼症
  • 眼癌
  • 地理萎缩
  • 青光眼
  • 角膜炎
  • 晶状体混浊和人工水晶体
  • 视网膜静脉阻塞

第八章光学疾病治疗市场：依最终使用者分类

  • 诊断中心
  • 眼科诊所
  • 医院
  • 病人

第九章 北美、南美光学疾病治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太视光疾病治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章 欧洲/中东/非洲眼科疾病治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Bausch & Lomb Incorporated
  • Bayer AG
  • Cipla Limited
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline PLC
  • Kiora Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Nicox SA
  • Novartis AG
  • Pfizer, Inc.
  • Regeneron Pharmaceuticals Inc
  • Santen Pharmaceutical Co., Ltd.
  • Senju Pharmaceutical Co., Ltd.
  • Sun Pharmaceutical Industries Ltd.
Product Code: MRR-434CCDA05224

The Optical Disorders Drugs Market was valued at USD 3.14 billion in 2023, expected to reach USD 3.56 billion in 2024, and is projected to grow at a CAGR of 13.29%, to USD 7.54 billion by 2030.

The scope of the optical disorders drugs market encompasses medications intended to treat various eye conditions, such as glaucoma, macular degeneration, diabetic retinopathy, and cataracts. These drugs are critical for maintaining eye health and vision, often acting by reducing intraocular pressure, slowing disease progression, or preventing infection. The necessity for such medications is underscored by the growing prevalence of optical disorders due to aging populations and increasing incidences of diabetes and other health conditions that can affect vision. These treatments find application in hospitals, clinics, and home care settings, ensuring a broad end-use scope.

KEY MARKET STATISTICS
Base Year [2023] USD 3.14 billion
Estimated Year [2024] USD 3.56 billion
Forecast Year [2030] USD 7.54 billion
CAGR (%) 13.29%

Market growth is significantly influenced by technological advancements in drug formulations and delivery methods, increased healthcare spending, particularly in emerging economies, and rising awareness of preventative eye care. Innovation in areas such as gene therapy, personalized medicine, and the development of novel drug delivery systems like sustained-release implants present promising opportunities. Notably, collaborations and partnerships among biotech firms and research institutions can drive market advancement.

However, the market confronts several challenges, including high R&D costs leading to expensive treatments, regulatory hurdles that can delay drug approval processes, and limited accessibility in underdeveloped regions. Furthermore, the competitive landscape is intense, with numerous players striving for a share of the market, potentially leading to high pricing pressure.

To capitalize on market opportunities, companies should focus on research areas such as regenerative medicine and biologics, which hold the potential for breakthroughs in treatment efficacy and patient outcomes. Firms are also encouraged to invest in digital health solutions and teleophthalmology to reach underserved markets effectively. The nature of the market remains dynamic, driven by rapid technological advancements and evolving patient needs, requiring continuous innovation and strategic adaptability to sustain growth and relevance.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Optical Disorders Drugs Market

The Optical Disorders Drugs Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising demand owing to increased digital exposure and unhealthy lifestyle
    • Prevalence of eye related disorders in geriatric population
    • Rise in the use of contact lenses and related disorders
  • Market Restraints
    • High treatment cost and lack of health insurance in developing economies
  • Market Opportunities
    • Technological advancements in optic drugs
    • Rising prevalence of glaucoma and an increase in healthcare expenditure
  • Market Challenges
    • Adverse health impacts of drugs

Porter's Five Forces: A Strategic Tool for Navigating the Optical Disorders Drugs Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Optical Disorders Drugs Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Optical Disorders Drugs Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Optical Disorders Drugs Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Optical Disorders Drugs Market

A detailed market share analysis in the Optical Disorders Drugs Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Optical Disorders Drugs Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Optical Disorders Drugs Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Optical Disorders Drugs Market

A strategic analysis of the Optical Disorders Drugs Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Optical Disorders Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Bausch & Lomb Incorporated, Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd, GlaxoSmithKline PLC, Kiora Pharmaceuticals, Inc., Merck & Co., Inc., Nicox SA, Novartis AG, Pfizer, Inc., Regeneron Pharmaceuticals Inc, Santen Pharmaceutical Co., Ltd., Senju Pharmaceutical Co., Ltd., and Sun Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Optical Disorders Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Prescription Type, market is studied across Over-The-Counter Drugs and Prescription Ophthalmic Drugs.
  • Based on Therapeutics, market is studied across Age-Related Macular Degeneration, Conjunctivitis, Diabetic Macular Edema, Diabetic Retinopathy, Dry Eye, Eye Cancer, Geographic Atrophy, Glaucoma, Keratitis, Lens Opacification & Intraocular Lens, and Retinal Vein Occlusion.
  • Based on End-User, market is studied across Diagnostic Centers, Eye Clinics, Hospitals, and Patient.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising demand owing to increased digital exposure and unhealthy lifestyle
      • 5.1.1.2. Prevalence of eye related disorders in geriatric population
      • 5.1.1.3. Rise in the use of contact lenses and related disorders
    • 5.1.2. Restraints
      • 5.1.2.1. High treatment cost and lack of health insurance in developing economies
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements in optic drugs
      • 5.1.3.2. Rising prevalence of glaucoma and an increase in healthcare expenditure
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse health impacts of drugs
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Optical Disorders Drugs Market, by Prescription Type

  • 6.1. Introduction
  • 6.2. Over-The-Counter Drugs
  • 6.3. Prescription Ophthalmic Drugs

7. Optical Disorders Drugs Market, by Therapeutics

  • 7.1. Introduction
  • 7.2. Age-Related Macular Degeneration
  • 7.3. Conjunctivitis
  • 7.4. Diabetic Macular Edema
  • 7.5. Diabetic Retinopathy
  • 7.6. Dry Eye
  • 7.7. Eye Cancer
  • 7.8. Geographic Atrophy
  • 7.9. Glaucoma
  • 7.10. Keratitis
  • 7.11. Lens Opacification & Intraocular Lens
  • 7.12. Retinal Vein Occlusion

8. Optical Disorders Drugs Market, by End-User

  • 8.1. Introduction
  • 8.2. Diagnostic Centers
  • 8.3. Eye Clinics
  • 8.4. Hospitals
  • 8.5. Patient

9. Americas Optical Disorders Drugs Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Optical Disorders Drugs Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Optical Disorders Drugs Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Bausch & Lomb Incorporated
  • 3. Bayer AG
  • 4. Cipla Limited
  • 5. F. Hoffmann-La Roche Ltd
  • 6. GlaxoSmithKline PLC
  • 7. Kiora Pharmaceuticals, Inc.
  • 8. Merck & Co., Inc.
  • 9. Nicox SA
  • 10. Novartis AG
  • 11. Pfizer, Inc.
  • 12. Regeneron Pharmaceuticals Inc
  • 13. Santen Pharmaceutical Co., Ltd.
  • 14. Senju Pharmaceutical Co., Ltd.
  • 15. Sun Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. OPTICAL DISORDERS DRUGS MARKET RESEARCH PROCESS
  • FIGURE 2. OPTICAL DISORDERS DRUGS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. OPTICAL DISORDERS DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. OPTICAL DISORDERS DRUGS MARKET DYNAMICS
  • TABLE 7. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION OPHTHALMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY AGE-RELATED MACULAR DEGENERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY CONJUNCTIVITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC MACULAR EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIABETIC RETINOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DRY EYE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GEOGRAPHIC ATROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY GLAUCOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY KERATITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY LENS OPACIFICATION & INTRAOCULAR LENS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY RETINAL VEIN OCCLUSION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY EYE CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PATIENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 29. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 33. ARGENTINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 36. BRAZIL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 59. INDIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 62. INDONESIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 65. JAPAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 68. MALAYSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 71. PHILIPPINES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 74. SINGAPORE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 77. SOUTH KOREA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 80. TAIWAN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 83. THAILAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 86. VIETNAM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 91. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 93. DENMARK OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 96. EGYPT OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 99. FINLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 102. FRANCE OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 105. GERMANY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 108. ISRAEL OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 111. ITALY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 114. NETHERLANDS OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 117. NIGERIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 120. NORWAY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 123. POLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 126. QATAR OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 129. RUSSIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 132. SAUDI ARABIA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH AFRICA OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 138. SPAIN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 141. SWEDEN OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 144. SWITZERLAND OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 147. TURKEY OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 150. UNITED ARAB EMIRATES OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY PRESCRIPTION TYPE, 2018-2030 (USD MILLION)
  • TABLE 152. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
  • TABLE 153. UNITED KINGDOM OPTICAL DISORDERS DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. OPTICAL DISORDERS DRUGS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 155. OPTICAL DISORDERS DRUGS MARKET, FPNV POSITIONING MATRIX, 2023